

Updates in COVID-19 Pharmacotherapy References

Special Guests: Amy Dzierba, PharmD, FCCM, FCCP, BCCCP
Mitchell Buckley, PharmD, FASHP, FCCM, FCCP, BCCP

Guidelines

Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. *Crit Care Med*. 2021; 49(3): e219-e234. <https://pubmed.ncbi.nlm.nih.gov/33555780/>

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 04/28/21.

Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. *Eur Respir J*. 2021; 57(4): 2100048. <https://pubmed.ncbi.nlm.nih.gov/33692120/>

Articles Referenced

Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N Eng J Med* 2021; 384(16): 1503-1516. <https://pubmed.ncbi.nlm.nih.gov/33631066/>

Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Eng J Med* 2021; 384(1): 20-30. <https://pubmed.ncbi.nlm.nih.gov/33332779/>

REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Eng J Med* 2021; 384(16): 1491-1502. <https://pubmed.ncbi.nlm.nih.gov/33631065/>

RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. *MedRxiv* doi: <https://doi.org/10.1101/2021.02.11.21249258>.
<https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1>

RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Eng J Med*. 2021; 384(8): 693-704.

<https://pubmed.ncbi.nlm.nih.gov/32678530/>

Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med*. 2020; 8(3): 267-276. <https://pubmed.ncbi.nlm.nih.gov/32043986/>

Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*. 2020; 324(13): 1307-1316.

<https://pubmed.ncbi.nlm.nih.gov/32876695/>

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol*. 2020; 7(6): e438-e440.

<https://pubmed.ncbi.nlm.nih.gov/32407672/>

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Eng J Med*. 2020; 383(2): 120-128.

<https://pubmed.ncbi.nlm.nih.gov/32437596/>

Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020; 75(23): 2950-2973.

<https://pubmed.ncbi.nlm.nih.gov/32311448/>

ATTACC, ACTIV-4a, and REMAP-CAP Multiplatform RCT interim analysis results.

<https://www.attacc.org/presentations>

Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. *BMJ*. 2021; 372: n311. <https://pubmed.ncbi.nlm.nih.gov/33574135/>

Other Resources

SCCM COVID-19 Webinars (One features Drs. Buckley and Dzierba)

<https://covid19.sccm.org/webcast/>